Yue Wu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1045929/publications.pdf

Version: 2024-02-01

| | | 1684188 | 2053705 |
|---------------|---------------------|-------------------|-----------------------|
| 5 | 74 | 5 | 5 |
| papers | citations | h-index | g-index |
| | | | |
| 5 all docs | 5 docs citations | 5 times ranked | 109 citing authors |

| # | Article | IF | CITATIONS |
|---|---|-----|-----------|
| 1 | Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 <i>H</i> -1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia. Journal of Medicinal Chemistry, 2018, 61, 5332-5349. | 6.4 | 35 |
| 2 | Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Journal of Medicinal Chemistry, 2020, 63, 10045-10060. | 6.4 | 16 |
| 3 | Small-molecule inhibitors of HIF-PHD2: a valid strategy to renal anemia treatment in clinical therapy. MedChemComm, 2016, 7, 1271-1284. | 3.4 | 11 |
| 4 | Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 3891-3899. | 3.0 | 7 |
| 5 | An improved and scalable synthesis of N-(5-(4-cyanophenyl)-3-hydroxypicolinoyl)glycine, a promising PHD2 inhibitor for the treatment of anemia. Tetrahedron Letters, 2015, 56, 5017-5019. | 1.4 | 5 |